In particular, the risk of AML occurring is more than 10 times higher in eastern Europe, with invasive AML at a rate of 2.5 per 1000 person-years.
Considering this, the doctors had to withdraw V-IVT.
Myeloid leukemia is a rare type of leukemia, mainly affecting elderly people.
About 10 percent of newly diagnosed cases develop AML.
The severity of AML correlates with that of experimental tumor cells.
Patients with AML tend to have a shorter survival time with a median survival period of 4.5 years.
